Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...
Lilly is currently waiting for the U.S. Food and Drug Administration’s (FDA’s) decision to expand the use of tirzepatide to ...
Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback